Basilea Pharmaceutica AG (BSLN.SW)

CHF 41.65

(0.24%)

Long Term Debt Summary of Basilea Pharmaceutica AG

Basilea Pharmaceutica AG's latest annual long term debt in 2023 was 95.45 Million CHF , down -27.33% from previous year.
Basilea Pharmaceutica AG's latest quarterly long term debt in 2024 Q2 was 95.68 Million CHF , down 0.0% from previous quarter.
Basilea Pharmaceutica AG reported annual long term debt of 131.36 Million CHF in 2022, up 38.94% from previous year.
Basilea Pharmaceutica AG reported annual long term debt of 94.54 Million CHF in 2021, down -60.55% from previous year.
Basilea Pharmaceutica AG reported quarterly long term debt of 95.45 Million CHF for 2023 Q4, down 0.0% from previous quarter.
Basilea Pharmaceutica AG reported quarterly long term debt of 113.17 Million CHF for 2023 Q2, down 0.0% from previous quarter.

Annual Long Term Debt Chart of Basilea Pharmaceutica AG (2023 - 2002)

Historical Annual Long Term Debt of Basilea Pharmaceutica AG (2023 - 2002)

Year	Long Term Debt	Long Term Debt Growth
2023	95.45 Million CHF	-27.33%
2022	131.36 Million CHF	38.94%
2021	94.54 Million CHF	-60.55%
2020	239.66 Million CHF	21.2%
2019	197.74 Million CHF	0.38%
2018	196.98 Million CHF	0.39%
2017	196.22 Million CHF	0.39%
2016	195.46 Million CHF	0.39%
2015	194.7 Million CHF	0.0%
2014	- CHF	0.0%
2013	- CHF	0.0%
2012	- CHF	0.0%
2011	- CHF	0.0%
2010	- CHF	0.0%
2009	- CHF	0.0%
2008	- CHF	0.0%
2007	- CHF	0.0%
2006	- CHF	0.0%
2005	- CHF	-100.0%
2004	19.1 Thousand CHF	-99.82%
2003	10.38 Million CHF	-2.19%
2002	10.61 Million CHF	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q2	95.68 Million CHF	0.0%
2023 Q4	95.45 Million CHF	0.0%
2023 Q2	113.17 Million CHF	0.0%
2023 FY	95.45 Million CHF	-27.33%
2022 FY	131.36 Million CHF	38.94%
2022 Q4	131.36 Million CHF	0.0%
2022 Q2	94.77 Million CHF	0.0%
2021 FY	94.54 Million CHF	-60.55%
2021 Q2	227.86 Million CHF	0.0%
2021 Q4	94.54 Million CHF	0.0%
2020 Q4	239.66 Million CHF	0.0%
2020 Q2	198.11 Million CHF	0.0%
2020 FY	239.66 Million CHF	21.2%
2019 Q2	197.35 Million CHF	0.0%
2019 FY	197.74 Million CHF	0.38%
2019 Q4	197.74 Million CHF	0.0%
2018 FY	196.98 Million CHF	0.39%
2018 Q4	196.98 Million CHF	0.0%
2018 Q2	196.6 Million CHF	0.0%
2017 Q4	196.22 Million CHF	0.0%
2017 Q2	195.84 Million CHF	0.0%
2017 FY	196.22 Million CHF	0.39%
2016 Q4	195.46 Million CHF	0.0%
2016 Q2	195.08 Million CHF	0.0%
2016 FY	195.46 Million CHF	0.39%
2015 Q2	- CHF	0.0%
2015 Q4	194.7 Million CHF	0.0%
2015 FY	194.7 Million CHF	0.0%
2014 FY	- CHF	0.0%
2014 Q4	- CHF	0.0%
2014 Q2	- CHF	0.0%
2013 Q2	- CHF	0.0%
2013 FY	- CHF	0.0%
2013 Q4	- CHF	0.0%
2012 Q2	- CHF	0.0%
2012 FY	- CHF	0.0%
2012 Q4	- CHF	0.0%
2011 FY	- CHF	0.0%
2011 Q2	- CHF	0.0%
2011 Q4	- CHF	0.0%
2010 Q2	- CHF	0.0%
2010 FY	- CHF	0.0%
2010 Q4	- CHF	0.0%
2009 Q4	- CHF	0.0%
2009 FY	- CHF	0.0%
2008 FY	- CHF	0.0%
2007 FY	- CHF	0.0%
2006 FY	- CHF	0.0%
2005 FY	- CHF	-100.0%
2004 FY	19.1 Thousand CHF	-99.82%
2003 FY	10.38 Million CHF	-2.19%
2002 FY	10.61 Million CHF	0.0%

Peer Long Term Debt Comparison of Basilea Pharmaceutica AG

Name	Long Term Debt	Long Term Debt Difference
Addex Therapeutics Ltd	70.38 Thousand CHF	-135528.019%
BB Biotech AG	304.9 Million CHF	68.693%
Evolva Holding SA	- CHF	-Infinity%
Idorsia Ltd	931 Million CHF	89.747%
Kuros Biosciences AG	1.56 Million CHF	-5999.361%
Molecular Partners AG	2.44 Million CHF	-3805.687%
Relief Therapeutics Holding AG	9000.00 CHF	-1060511.111%
Santhera Pharmaceuticals Holding AG	1.47 Million CHF	-6358.39%